Cas:60609-65-6 1-(4-Methoxy-3,5-dimethylphenyl)ethanone manufacturer & supplier

Chemical Name:1-(4-Methoxy-3,5-dimethylphenyl)ethanone

CAS.NO:60609-65-6

Synonyms:1-(4-Methoxy-3,5-dimethylphenyl)ethanone;Ethanone, 1-(4-methoxy-3,5-dimethylphenyl)-

Molecular Formula:C₁₁H₁₄O₂

Molecular Weight:178.228

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:291.4±35.0 °C at 760 mmHg

Density:1.0±0.1 g/cm3

Index of Refraction:1.505

PSA:26.30000

Exact Mass:178.099380

LogP:2.66

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-(4-Methoxy-3,5-dimethylphenyl)ethanone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Ethanone, 1-(4-methoxy-3,5-dimethylphenyl)- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-(4-Methoxy-3,5-dimethylphenyl)ethanone Use and application,Ethanone, 1-(4-methoxy-3,5-dimethylphenyl)- technical grade,usp/ep/jp grade.

Related News: For these reasons, many pharmaceutical companies are choosing to evaluate biocatalytic processes during early-stage drug development to avoid missing opportunities for capitalizing on these gains. (5Z,7E,22E)-(1S,3R,24S)-20-methyl-25-(5-methylthiazol-2-yl)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol manufacturers One way of leveraging the many benefits of biocatalysis is to partner with an API CDMO offering comprehensive expertise and experience in developing and implementing such technology in GMP commercial production. 2,4-bis(2,4,6-tri-tert-butylphenyl)bicyclo[1.1.0]tetraphosphane suppliers As part of the strategy, the government will review the research funding offer to retain, attract and support the very best researchers, innovators and their teams. 1-(2-Cyanoethyl)-1-ethyl-harnstoff vendor & factory As part of the strategy, the government will review the research funding offer to retain, attract and support the very best researchers, innovators and their teams.,For these reasons, many pharmaceutical companies are choosing to evaluate biocatalytic processes during early-stage drug development to avoid missing opportunities for capitalizing on these gains.